
The U.S. Supreme Court agreed to hear Hikma v. Amarin to answer a narrow question. It may end up saying far more about how policymakers misunderstand pharmaceutical markets. On its face, the case is narrow. It asks whether a generic drug manufacturer can face liability for inducing patent infringement based on how it markets a…
The Fatal Conceit of Cheap Drugs
Apr 07, 2026 @ 15:54:53
Thanks Jim,I enjoy reading the articles you highlight.
I read this article with a continuing belief that the author was stomping on Generics in favour of the Pharma companies.
I did not find his arguments re inovation as compelling given that generics are only allowed after Patents expire.
iethe Hatch-Waxman Act—a statute meant to balance innovation and competition. The premise was simple: allow generics to enter quickly after patent expiration
I then looked up the author and found.
Previously, Depp was senior director of intellectual property at the Pharmaceutical Research and Manufacturers of America (PhRMA).
I suggest this author does not take in to account the low cost generics effect on the health of the rest of the world.
LikeLiked by 1 person